Disclosures for "Individual Alpha Frequency for Diagnosis and Prognosis in Dementia"
-
Giordano Cecchetti has nothing to disclose.
-
Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
-
The institution of Elisa Canu has received research support from Italian Ministry of Health .
-
Silvia Basaia has nothing to disclose.
-
Dr. Rugarli has nothing to disclose.
-
Dr. Curti has nothing to disclose.
-
Dr. Coraglia has nothing to disclose.
-
Marco Cursi has nothing to disclose.
-
Dr. Spinelli has nothing to disclose.
-
Roberto Santangelo, 4503 has nothing to disclose.
-
Dr. Caso has nothing to disclose.
-
Dr. Fanelli has nothing to disclose.
-
Giuseppe Magnani has nothing to disclose.
-
Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi;. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi- Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.